文献速递白血病MDS 与骨髓增殖性肿瘤

维奈克拉联合方案治疗MPN进展后AML的单中心经验

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
PubMed 文献 · Blood Adv · 2021-01-01

该单中心回顾性分析纳入14例初诊和17例复发/难治性MPN进展后AML患者,评估维奈克拉联合方案的疗效与安全性。初诊患者中6例达完全缓解(中位持续6.4个月),1例部分缓解,中位总生存7个月;复发/难治患者无正式缓解,中位总生存3个月。83%患者初始周期发生≥3级感染,14例严重出血,4周和8周死亡率分别为10%和32%。

要点

  • 初诊MPN进展后AML患者维奈克拉联合方案中位OS仅7个月,缓解短暂。
  • 复发/难治患者无正式缓解,中位OS 3个月,疗效极差。
  • 83%患者初始周期发生≥3级感染,14例严重出血,8周死亡率达32%。

核心结论

  • 维奈克拉联合方案在初诊MPN进展后AML中仅带来短暂缓解,在复发/难治患者中无正式缓解,且治疗相关血液学毒性和死亡率显著。

研究设计与样本

  • 单中心回顾性分析,纳入14例初诊和17例复发/难治性MPN进展后AML患者,评估维奈克拉联合方案的疗效与安全性。

主要发现

  • 初诊患者中6例达完全缓解(伴或不伴血细胞计数恢复),中位持续时间6.4个月,1例部分缓解,中位总生存7个月。
  • 复发/难治患者中未见正式缓解,中位总生存3个月。
  • 83%患者初始周期发生≥3级感染,14例发生严重出血并发症(包括6例颅内和硬膜下出血)。
  • 总体4周和8周死亡率分别为10%和32%。

关键数值与推荐

  • 维奈克拉初始周期中位剂量为100 mg(范围50-800 mg),初诊患者为200 mg(范围100-800 mg)。
  • 58%病例维奈克拉与低甲基化剂联合,19%与强化化疗(含阿糖胞苷≥1 g/m2或CPX-351)联合。
  • 其余患者接受克拉屈滨联合低剂量阿糖胞苷或IDH1/2抑制剂。
  • 与唑类抗真菌药联用时调整维奈克拉剂量。

临床怎么用

  • 对于MPN进展后AML患者,维奈克拉联合方案疗效有限且毒性显著,需谨慎评估获益风险。
  • 治疗期间应密切监测感染和出血并发症,尤其是严重出血事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with acute myeloid leukemia evolving from myeloproliferative neoplasms (post-MPN-AML), the clinical activity of the B-cell lymphoma 2 inhibitor venetoclax remains to be determined. We review our experience with venetoclax-based regimens in 14 newly diagnosed (frontline [FL]) and 17 relapsed/refractory (R/R) post-MPN-AML patients. Venetoclax was used in combination with hypomethylating agents in 58% of cases and in 19% with intensive chemotherapy (treatment including cytarabine ≥1 g/m2 or CPX-351); the remaining patients received cladribine and low-dose cytarabine or isocitrate dehydrogenase 1/2 inhibitors. The median dose of venetoclax during the initial cycle was 100 mg in all patients (range, 50-800 mg) and 200 mg (range, 100-800 mg) for FL patients. The venetoclax dose was adjusted when used concomitantly with azole antifungal agents. In FL patients, complete remission with and without count recovery in 6 patients (median duration of 6.4 months) and partial remission in 1 patient was noted, with a median overall survival of 7 months. In R/R patients, no formal responses were seen, with a median overall survival of 3 months. Hematologic toxicities and adverse events were frequent; 83% of patients developed grade 3 or higher infection during the initial cycle. Severe hemorrhagic complications were observed in 14 patients, including 6 cases of intracranial and subdural hemorrhage. Overall 4-week and 8-week mortality were 10% and 32%, respectively. Given the substantial treatment-associated hematologic toxicity and mortality, and modest short-lived responses only in newly diagnosed patients with venetoclax-based regimens, additional treatment options are urgently needed for these patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Masarova L, DiNardo CD, Bose P, et al. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021. PMID: 33885751. doi:10.1182/bloodadvances.2020003934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。